Several additional clinical trials have been registered [40], and similarly, antibodies against the interleukin 6 (IL-6) receptor [41,42] and IL-6 itself are under development for the treatment of the acute respiratory distress syndrome (ARDS) suffered by some COVID-19 patients [42]. This evidence concerns the gene IL6 and acute respiratory distress syndrome.